The biopharmaceutical company Aceragen has formally entered liquidation following the cessation of its business operations. Stakeholders are now awaiting specifics on the distribution of remaining funds as the company’s assets are sold off.
Aceragen has effectively ceased to exist as a publicly traded entity. Trading on major exchanges has been permanently halted as the company transitions into a structured wind-down. This administrative phase focuses on settling outstanding obligations using the firm’s remaining resources. The liquidation is being managed through an out-of-court insolvency proceeding known as a General Assignment for the Benefit of Creditors (GABC).
Key Asset and Legal Proceedings
The central variable determining final…